新股消息 | 益方生物拟港股上市 中国证监会要求补充说明安全生产合规情况

Group 1 - The China Securities Regulatory Commission (CSRC) has issued supplementary material requirements for four companies, including Yifang Biotechnology, which is required to clarify compliance operations related to safety production [1] - Yifang Biotechnology has submitted a listing application to the Hong Kong Stock Exchange, with CITIC Securities as its sole sponsor [1] - The CSRC has requested Yifang Biotechnology to provide legal opinions regarding its business scope and whether it involves restricted foreign investment areas, as well as compliance with foreign investment policies [1] Group 2 - As of December 24, 2025, the company has established a comprehensive and differentiated product pipeline, including two commercialized products (Befotizumab and Gexorase), two core products in clinical stages (D-2570 and Terysqun), one clinical candidate (Dabinoside), and three preclinical candidates (YF087, YF550, and YF057) [2]